Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EMB-02 |
Synonyms | |
Therapy Description |
EMB-02 is a bispecific antibody that targets both PD-1 (CD279) and lymphocyte activation gene 3 protein (LAG-3), which degrades PD-1- and LAG-3 to induce T cell effector function, potentially leading to a cytotoxic T lymphocyte response against tumor cells (NCI Drug Dictionary, Ann Oncol 34 (2023): S625). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EMB-02 | EMB 02|EMB02 | Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 PD-L1/PD-1 antibody 121 | EMB-02 is a bispecific antibody that targets both PD-1 (CD279) and lymphocyte activation gene 3 protein (LAG-3), which degrades PD-1- and LAG-3 to induce T cell effector function, potentially leading to a cytotoxic T lymphocyte response against tumor cells (NCI Drug Dictionary, Ann Oncol 34 (2023): S625). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04618393 | Phase Ib/II | EMB-02 | A Study of EMB-02 in Participants With Advanced Solid Tumors | Terminated | USA | AUS | 1 |